(NewsNation) — Eli Lilly announced Thursday its experimental weight-loss pill passed its first late-stage trial among patients with diabetes, delivering on the company’s promise to lower blood ...

(Reuters) -Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S. judge last month blocked pharmacies from making copies of ...

Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ratings for the stock.Despite broader market uncertainties, the company ...